Chemical Engineering of Natural Killer Cells for Cancer Immunotherapy

Project description

Engineered NK cells against cancer

Tumours have evolved mechanisms for evading immune system responses including T cell exhaustion. To address this problem, scientists have come up with immunotherapy strategies to awaken or reeducate the immune system against cancer. Chimeric antigen receptor (CAR) natural killer (NK) cells are genetically engineered to recognise a specific target antigen. Despite their great promise, CAR-NK cell production is laborious and costly. The ERC-funded CHEMCELL project aims to address this limitation through an innovative labelling and engineering approach. Researchers will produce antibody-modified NK cells and test them against conventional CAR-NK cells for their anti-cancer efficiency.

Fields of science

• engineering and technology › industrial biotechnology › metabolic engineering
• medical and health sciences › clinical medicine › oncology
• engineering and technology › chemical engineering
• medical and health sciences › basic medicine › immunology › immunotherapy

Programme(s)

• HORIZON.1.1 - European Research Council (ERC) Main Programme

Topic(s)

• ERC-2022-POC2 - ERC PROOF OF CONCEPT GRANTS2

Call for proposal

ERC-2022-POC2

See other projects for this call

Funding Scheme

HORIZON-AG-LS - HORIZON Lump Sum Grant

Coordinator

USTAV ORGANICKE CHEMIE A BIOCHEMIE, AV CR, V.V.I.

Net EU contribution

€ 150 000,00

Address

Flemingovo Nam. 542/2
16610 Praha 6
Czechia

Region

Praha › Hlavní město Praha

Activity type

Research Organisations

Links

Other funding

No data